Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.51 |
| ▸ | NPC1 | O15118 | 1/20 | 0.51 |
| ▸ | PKM | P14618 | 1/20 | 0.51 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.51 |
| ▸ | RAB9A | P51151 | 1/20 | 0.51 |
| ▸ | DRD2 | P14416 | 1/20 | 0.49 |
| ▸ | DRD3 | P35462 | 1/20 | 0.49 |
| ▸ | MTNR1A | P48039 | 7/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | TP53 | P04637 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.49 |
| ▸ | MTNR1B | P49286 | 6/20 | 0.48 |
| ▸ | NAAA | Q02083 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21682750 | 0.96 | NAMPT (0.55) | NAMPTSMN1; SMN2NPC1PKMEPHX2 | |
| SCHEMBL6076194 | 0.81 | MTNR1A (0.62) | MTNR1AMTNR1B | |
| SCHEMBL5815460 | 0.80 | EPHX1 (0.66) | SMN1; SMN2NPC1PKMEPHX2RAB9A | |
| SCHEMBL18342995 | 0.79 | EPHX1 (0.63) | SMN1; SMN2NPC1PKMEPHX2RAB9A | |
| SCHEMBL528127 | 0.78 | HPGD (0.42) | SMN1; SMN2NPC1PKMEPHX2RAB9A | |
| SCHEMBL5340060 | 0.77 | MTNR1A (0.64) | MTNR1AMTNR1B | |
| SCHEMBL2795464 | 0.76 | MTNR1A (0.59) | SMN1; SMN2NPC1PKMEPHX2RAB9A | |
| SCHEMBL5346108 | 0.76 | MTNR1A (0.62) | MTNR1AMTNR1B | |
| SCHEMBL5337721 | 0.76 | MTNR1A (0.62) | MTNR1AMTNR1B | |
| SCHEMBL9131349 | 0.76 | MTNR1A (0.69) | MTNR1AMTNR1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3833336-A1 | METHODS FOR DELAYING OCCURRENCE OF NEW-ONSET TYPE 2 DIABETES AND FOR SLOWING PROGRESSION OF AND TREATING TYPE 2 DIABETES | DalCor Pharma UK Ltd Leatherhead, Zug Branch (CH) | 2021-06-16 | — | — | EP | claimed |
| WO-2020030814-A1 | METHODS FOR DELAYING OCCURRENCE OF NEW-ONSET TYPE 2 DIABETES AND FOR SLOWING PROGRESSION OF AND TREATING TYPE 2 DIABETES | DALCOR PHARMA UK LTD., LEATHERHEAD, ZUG BRANCH (CH) | 2020-02-13 | — | — | WO | claimed |
| EP-3261628-A1 | CHOLESTERYL ESTER TRANSFER PROTEIN (CETP) INHIBITION IN THE TREATMENT OF CANCER | King Abdullah University Of Science And Technology (SA) | 2018-01-03 | — | — | EP | claimed |
| WO-2016135633-A1 | CHOLESTERYL ESTER TRANSFER PROTEIN (CETP) INHIBITION IN THE TREATMENT OF CANCER | KING ABDULLAH UNIVERSITY OF SCIENCE & TECHNOLOGY (SA) | 2016-09-01 | — | — | WO | claimed |
| EP-1603553-A2 | PHARMACEUTICAL COMPOSITIONS OF CETP INHIBITORS | JAPAN TOBACCO INC. (JP) | 2005-12-14 | — | — | EP | claimed |
| WO-2004082593-A2 | PHARMACEUTICAL COMPOSITIONS OF CETP INHIBITORS | JAPAN TOBACCO INC. (JP) | 2004-09-30 | — | — | WO | claimed |
| EP-3833336-A1 | METHODS FOR DELAYING OCCURRENCE OF NEW-ONSET TYPE 2 DIABETES AND FOR SLOWING PROGRESSION OF AND TREATING TYPE 2 DIABETES | DalCor Pharma UK Ltd Leatherhead, Zug Branch (CH) | 2021-06-16 | — | — | EP | disclosed |
| WO-2020030814-A1 | METHODS FOR DELAYING OCCURRENCE OF NEW-ONSET TYPE 2 DIABETES AND FOR SLOWING PROGRESSION OF AND TREATING TYPE 2 DIABETES | DALCOR PHARMA UK LTD., LEATHERHEAD, ZUG BRANCH (CH) | 2020-02-13 | — | — | WO | disclosed |
| EP-3261628-A1 | CHOLESTERYL ESTER TRANSFER PROTEIN (CETP) INHIBITION IN THE TREATMENT OF CANCER | King Abdullah University Of Science And Technology (SA) | 2018-01-03 | — | — | EP | disclosed |
| WO-2016135633-A1 | CHOLESTERYL ESTER TRANSFER PROTEIN (CETP) INHIBITION IN THE TREATMENT OF CANCER | KING ABDULLAH UNIVERSITY OF SCIENCE & TECHNOLOGY (SA) | 2016-09-01 | — | — | WO | disclosed |
| EP-2598158-A1 | PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF LEFT VENTRICULAR DIASTOLIC DYSFUNCTION COMPRISING AN APOLIPOPROTEIN PEPTIDE/PHOSPHOLIPID COMPLEX | Institut de Cardiologie de Montréal (CA) | 2013-06-05 | — | — | EP | disclosed |
| WO-2012012870-A1 | PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF LEFT VENTRICULAR DIASTOLIC DYSFUNCTION COMPRISING AN APOLIPOPROTEIN PEPTIDE/PHOSPHOLIPID COMPLEX | INSTITUT DE CARDIOLOGIE DE MONTREAL (CA) | 2012-02-02 | — | — | WO | disclosed |
| US-6753346-B2 | ANTICHOLESTEROL AGENTS; CARDIOVASCULAR DISORDERS; ANTILIPEMIC AGENTS | JAPAN TOBACCO INC. (JP) | 2004-06-22 | — | — | US | disclosed |
| US-20030092708-A1 | Anticholesterol agents; cardiovascular disorders; antilipemic agents | JAPAN TOBACCO, INC., A JAPAN CORPORATION | 2003-05-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030092708-A1 | Anticholesterol agents; cardiovascular disorders; antilipemic agents | CETP, CES1, PON1 | NAMPT 2487/4885SMN1; SMN2 4844/4885NPC1 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.